The White House launched a new cybersecurity safety label, the U.S. Cyber Trust Mark, intended to help consumers make ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Dalton, GA - November 17 - The Carpet and Rug Institute (CRI) has launched a new Seal of Approval program designed to recognize superior carpet cleaning products that pass stringent tests ...

It is available only through a restricted REMS program. The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Please provide your email address to receive an email when new articles are posted on . The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

This mark signals that a device meets a set of security features approved by the National Institute of Standards and Technology (NIST). Consumers will be able to scan a QR code next to the Cyber Trust ...

The FDA determined that due to substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products, the authorized nicotine pouches pose a lower risk for cancer ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment ...